Nursing interventions for adult patients undergoing cancer cardiotoxic therapy: Scoping review

Abstract

Purpose

To identify nursing interventions for the management of adult patients undergoing cardiotoxic oncologic therapy.

Methods

This scoping review was performed in accordance with the JBI guidelines. The literature search took place between July and August 2022. Studies examining interventions for the management of adult cancer patients undergoing cardiotoxic therapy were included. The characteristics and results of the studies were synthesized and analyzed in a narrative way.

Findings

In the nine included studies, it was verified that the interventions were implemented to guide the actions of the health team in general rather than specifically nursing staff. Nine nursing interventions related to the Classification of Nursing Interventions were included.

Conclusions

The nursing interventions identified focused on rigorous cardiovascular surveillance, risk assessment, and actions to identify and mitigate cardiotoxicity.

Implications for Nursing Practice

It is believed that the implementation of the identified nursing interventions will lead to evidence-based nursing practice and will contribute to the development of care products and processes that assess the cardiological risks and cardiotoxicity.

Objetivo

Identificar as intervenções de enfermagem no manejo de pacientes adultos submetidos à terapia oncológica cardiotóxica.

Métodos

Revisão de escopo seguindo a JBI. A busca da literatura ocorreu entre julho e agosto de 2022. Foram incluídos estudos que abordam intervenções para o manejo de pacientes adultos oncológicos submetidos à terapia cardiotóxica. As características e resultados foram sintetizados e analisados de forma narrativa.

Resultados

Nos nove estudos incluídos, verificou-se que as intervenções foram direcionadas às ações da equipe de saúde, em geral, e não àquelas específicas da enfermagem. A partir da literatura, foram identificadas nove intervenções de enfermagem relacionadas à Classificação das Intervenções de Enfermagem.

Conclusões

As intervenções de enfermagem identificadas direcionaram-se para vigilância cardiovascular rigorosa, avaliação de risco e ações para identificar e mitigar a cardiotoxicidade.

Implicações para a prática de enfermagem

Acredita-se que a implementação das intervenções identificadas proporcionará uma prática de enfermagem baseada em evidências e contribuirá para o desenvolvimento de produtos e processos assistenciais que avaliem os riscos cardiológicos e a cardiotoxicidade.

Keywords

cardio-oncology cardiotoxicity neoplasms oncology scoping review câncer cardiotoxicidade oncologia revisão de escopo

Get full access to this article

View all access options for this article.

References

Aleman

B. M. P.

vandenBelt-Dusebout

A. W.

De Bruin

M. L.

van’t Veer

M. B.

Baaijens

M. H. A.

Boer

J. P. D.

Hart

A. A. M.

Klokman

W. J.

Kuenen

M. A.

Ouwens

G. M.

Bartelink

vanLeeuwen

F. E.

(2007). Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood, 109(5), 1878–1886. https://doi.org/10.1182/blood-2006-07-034405

Barron

C. C.

Alhussein

M. M.

Kaur

Cosman

T. L.

Tyagi

N. K.

Brown

Mukherjee

S. D.

Ellis

P. M.

Dhesy-Thind

Leong

D. P.

(2019). An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. Current Oncology, 26(4), 240–246. https://doi.org/10.3747/co.26.4631

Baz

Kottke-Marchant

Srkalovic

McGowan

Yiannaki

Karam

M. A.

Faiman

Jawde

R. A.

Andresen

Zeldis

Hussein

M. A.

(2005). The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. Mayo Clinic Proceedings, 80(12), 1568–1574. https://doi.org/10.4065/80.12.1568

Bulechek

G. M.

Butcher

H. K.

Dochterman

J. M.

(2020). NIC–classification of nursing interventions (in Portuguese). GEN Guanabara Koogan.

Clarke

Lenihan

(2015). Cardio-oncology: A new discipline in medicine to lead us into truly integrative care. Future Cardiology, 11(4), 359–361. https://doi.org/10.2217/fca.15.55

Gilchrist

S. C.

Barac

Ades

P. A.

Alfano

C. M.

Franklin

B. A.

Jones

L. W.

La Gerche

Ligibel

J. A.

Lopez

Madan

Oeffinger

K. C.

Salamone

Scott

J. M.

Squires

R. W.

Thomas

R. J.

Treat-Jacobson

D. J.

Wright

J. S.

American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology, & Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease . (2019). Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: A scientific statement from the American Heart Association. Circulation, 139(21), e997–e1012. https://doi.org/10.1161/CIR.0000000000000679

Hajjar

L. A.

Costa

I. B. S. D. S. D.

Lopes

M. A. C. Q.

Hoff

P. M. G.

Diz

M. D. P. E.

Fonseca

S. M. R.

Bittar

C. S.

Rehder

M. H. H. D. S.

Rizk

S. I.

Almeida

D. R.

Fernandes

G. S.

Beck-da-Silva

Campos

C. A. H. M.

Montera

M. W.

Alves

S. M. M.

Fukushima

J. T.

Santos

M. V. C.

Negrão

C. E.

Silva

T. L. F.

, … Kalil Filho

(2020). Brazilian Cardio-oncology Guideline – 2020. Arquivos Brasileiros de Cardiologia, 115, 1006–1043. https://doi.org/10.36660/abc.20201006

Hajjar

L. A.

Filho

R. K.

Hoff

P. M. G.

(2018). Manual of conducts in cardio-oncology (in Portuguese). Atheneu.

Hameau

Gabrielli

Garrido

Guzmán

A. M.

Retamal

Vacarezza

M. J.

Greig

Ocqueteau

Sánchez

Pizarro

Corvalán

Lavandero

Castro

P. F.

Martínez

(2018). Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología. Revista Médica de Chile, 146(1), 68–77. https://doi.org/10.4067/s0034-98872018000100068

10.

Hardy

Liu

C. C.

Cormier

J. N.

Xia

X. L.

(2010). Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Annals of Oncology, 21(9), 1825–1833. https://doi.org/10.1093/annonc/mdq042

11.

Hortobagyi

G. N.

Frye

Buzdar

A. U.

Ewer

M. S.

Fraschini

Hug

Ames

Montague

Carrasco

C. H.

Mackay

Benjamin

R. S.

(1989). Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer, 63(1), 37–45. https://doi.org/10.1002/1097-0142(19890101)63:1<37::aid-cncr2820630106>3.0.co;2-z

12.

International Agency for Research on Cancer (IARC) . (2008). World Cancer Report 2008 . World Health Organization. https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2008

13.

Instituto Nacional de Câncer José Alencar Gomes da Silva . (2019). Estimate 2020: Incidence of cancer in Brazil. INCA.

14.

Lancellotti

Suter

T. M.

López-Fernández

Galderisi

Lyon

A. R.

Van der Meer

Cohen Solal

Zamorano

J.-L.

Jerusalem

Moonen

Aboyans

Bax

J. J.

Asteggiano

(2019). Cardio-oncology services: Rationale, organization, and implementation. European Heart Journal, 40(22), 1756–1763. https://doi.org/10.1093/eurheartj/ehy453

15.

Yang

Wang

Liu

Bai

Tian

Sun

Chu

(2021). Role of acetylation in doxorubicin-induced cardiotoxicity. Redox Biology, 46, 102089. https://doi.org/10.1016/j.redox.2021.102089

16.

Macedo

A. V. S.

(2017). Cardioprotection during cancer treatment. Revista da Sociedade de Cardiologia do Estado de São Paulo, 27(4), 313–318. https://doi.org/10.29381/0103-8559/20172704313-8

17.

Moher

Liberati

Tetzlaff

Altman

D. G.

PRISMA Group . (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Annals of Internal Medicine, 151(4), 264–269. w264. https://doi.org/10.7326/0003-4819-151-4-200908180-00135

18.

Osataphan

Phrommintikul

Chattipakorn

S. C.

Chattipakorn

(2020). Effects of doxorubicin-induced cardiotoxicity on cardiac mitochondrial dynamics and mitochondrial function: Insights for future interventions. Journal of Cellular and Molecular Medicine, 24(12), 6534–6557. https://doi.org/10.1111/jcmm.15305

19.

Oztop

Gencer

Okan

Yaren

Altekin

Turker

Yilmaz

(2004). Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers. Japanese Journal of Clinical Oncology, 34(5), 262–268. https://doi.org/10.1093/jjco/hyh047

20.

Peters

M. D. J.

Godfrey

Mclnerney

Munn

Tricco

A. C.

Khalil

(2020). Scoping reviews. In Aromataris

Munn

(Eds.), JBI manual for evidence synthesis. JBI. https://doi.org/10.46658/JBIMES-20-12

21.

Ping

Peng

Lang

Xinyong

Zhiyi

Xiaocheng

Hong

Liang

(2020). Oxidative stress in radiation-induced cardiotoxicity. Oxidative Medicine and Cellular Longevity, 2020, 3579143. https://doi.org/10.1155/2020/3579143

22.

Tang

X.-M.

Chen

Liu

Huang

B.-L.

Zhang

X.-Q.

Yuan

J.-M.

(2017). The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients. Medicine, 96(3), e5946. https://doi.org/10.1097/MD.0000000000005946

23.

Totzeck

Schuler

Stuschke

Heusch

Rassaf

(2019). Cardio-oncology – Strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology, 280, 163–175. https://doi.org/10.1016/j.ijcard.2019.01.038

24.

Trevisan

D. D.

Silva

J. B.

Oliveira

H. C.

Secoli

S. R.

Lima

M. H. M.

(2015). Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation. Cancer Chemotherapy and Pharmacology, 75(2), 393–400. https://doi.org/10.1007/s00280-014-2657-8

25.

Tricco

A. C.

Lillie

Zarin

O'Brien

K. K.

Colquhoun

Levac

Moher

Peters

M. D. J.

Horsley

Weeks

Hempel

Akl

E. A.

Chang

McGowan

Stewart

Hartling

Aldcroft

Wilson

M. G.

Garritty

, … Straus

S. E.

(2018). PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Annals of Internal Medicine, 169(7), 467–473. https://doi.org/10.7326/M18-0850

26.

vanDalen

E. C.

van derPal

H. J. H.

Kremer

L. C. M.

(2016). Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews, 3(3), CD005008. https://doi.org/10.1002/14651858.CD005008.pub4

27.

Xue

Jiang

Zhang

Wang

Zhang

(2014). Risk of trastuzumab-related cardiotoxicity in early breast cancer patients: A prospective observational study. Journal of Breast Cancer, 17(4), 363–369. https://doi.org/10.4048/jbc.2014.17.4.363

28.

Yeh

E. T. H.

(2006). Cardiotoxicity induced by chemotherapy and antibody therapy. Annual Review of Medicine, 57(1), 485–498. https://doi.org/10.1146/annurev.med.57.121304.131240

29.

Yeh

E. T. H.

Tong

A. T.

Lenihan

D. J.

Yusuf

S. W.

Swafford

Champion

Durand

J.-B.

Gibbs

Zafarmand

A. A.

Ewer

M. S.

(2004). Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation, 109(25), 3122–3131. https://doi.org/10.1161/01.cir.0000133187.74800.b9

30.

Yusuf

S. W.

Razeghi

Yeh

E. T. H.

(2008). The diagnosis and management of cardiovascular disease in cancer patients. Current Problems in Cardiology, 33(4), 163–196. https://doi.org/10.1016/j.cpcardiol.2008.01.002

31.

Zamorano

J. L.

Lancellotti

Muñoz

D. R.

Aboyans

Asteggiano

Galderisi

Habib

Lenihan

D. J.

Lip

G. Y. H.

Lyon

A. R.

Lopez Fernandez

Mohty

Piepoli

M. F.

Tamargo

Torbicki

Suter

T. M.

(2016). 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). European Heart Journal, 37(36), 2768–2801. https://doi.org/10.1093/eurheartj/ehw211